ANIP NASDAQ
ANI Pharmaceuticals, Inc.
1W: +0.1%
1M: -1.9%
3M: -10.4%
YTD: -7.4%
1Y: -23.5%
3Y: +26.7%
5Y: +92.2%
$71.17
-1.43 (-1.97%)
After Hours: $72.05 (+0.88, +1.24%)
Weekly Expected Move ±3.7%
$67
$70
$73
$75
$78
Credit Risk of going bust: lower than 74% of companies Debt: 16.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.02 (down 99%), ANI Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $330.3M against a stock market value of $1.67B.
Distance to default 8.26 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $175.8M (short-term plus half of long-term), stock volatility 31.3%; Altman Z 2.61. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $1.02 (down 99%), ANI Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $330.3M against a stock market value of $1.67B.
Distance to default 8.26 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $175.8M (short-term plus half of long-term), stock volatility 31.3%; Altman Z 2.61. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.7B
52W Range69.58-96.57
Volume223,862
Avg Volume366,459
Beta0.49
Dividend—
Analyst Ratings
Company Info
CEONikhil Lalwani
Employees970
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2000-05-05
Websiteanipharmaceuticals.com
210 Main Street West
Baudette, MN 56623
US
Baudette, MN 56623
US
218 634 3500
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Latest News
Oppenheimer's top 50 small- and mid-cap Sell ideas
ANI Pharmaceuticals (NASDAQ:ANIP) CEO Sells $388,206.00 in Stock
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
ANI Pharma reports positive phase 4 data for Iluvien in non-infectious uveitis
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Lalwani Nikhil | S-Sale | 5,400 | $71.89 | 2026-10-15 |
| Cook Meredith | S-Sale | 500 | $73.59 | 2026-10-13 |
| CAREY STEPHEN P. | S-Sale | 2,850 | $73.00 | 2026-09-29 |
| Lalwani Nikhil | S-Sale | 5,400 | $71.00 | 2026-09-15 |
| Cook Meredith | S-Sale | 500 | $70.79 | 2026-09-14 |